BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 37639015)

  • 21. Metformin in non-alcoholic fatty liver disease: A systematic review and meta-analysis.
    Li Y; Liu L; Wang B; Wang J; Chen D
    Biomed Rep; 2013 Jan; 1(1):57-64. PubMed ID: 24648894
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The effect of a fruit-rich diet on liver biomarkers, insulin resistance, and lipid profile in patients with non-alcoholic fatty liver disease: a randomized clinical trial.
    Alami F; Alizadeh M; Shateri K
    Scand J Gastroenterol; 2022 Oct; 57(10):1238-1249. PubMed ID: 35710164
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Investigation of the effects of Chlorella vulgaris supplementation in patients with non-alcoholic fatty liver disease: a randomized clinical trial.
    Panahi Y; Ghamarchehreh ME; Beiraghdar F; Zare R; Jalalian HR; Sahebkar A
    Hepatogastroenterology; 2012 Oct; 59(119):2099-2103. PubMed ID: 23234816
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Carotid intima-media thickness and flow-mediated dilation in obese children with non-alcoholic fatty liver disease.
    Torun E; Aydın S; Gökçe S; Özgen İT; Donmez T; Cesur Y
    Turk J Gastroenterol; 2014 Dec; 25 Suppl 1():92-8. PubMed ID: 25910377
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Screening for non-alcoholic fatty liver disease among obese and overweight children: Prevalence and predictors.
    Thiagarajan S; Shrinuvasan S; Arun Babu T
    Indian J Gastroenterol; 2022 Feb; 41(1):63-68. PubMed ID: 35064452
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effect of silymarin plus vitamin E in patients with non-alcoholic fatty liver disease. A randomized clinical pilot study.
    Aller R; Izaola O; Gómez S; Tafur C; González G; Berroa E; Mora N; González JM; de Luis DA
    Eur Rev Med Pharmacol Sci; 2015 Aug; 19(16):3118-24. PubMed ID: 26367736
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Therapeutic effects of insulin-sensitizing drugs on nonalcoholic fatty liver disease: experiment with rats].
    Zhang DM; Zhang GY; Wang T; Zhong HJ; Chen WK
    Zhonghua Yi Xue Za Zhi; 2006 May; 86(18):1279-83. PubMed ID: 16796890
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Increased serum concentration of ceramides in obese children with nonalcoholic fatty liver disease.
    Wasilewska N; Bobrus-Chociej A; Harasim-Symbor E; Tarasów E; Wojtkowska M; Chabowski A; Lebensztejn DM
    Lipids Health Dis; 2018 Sep; 17(1):216. PubMed ID: 30208901
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Omega-3 fatty acids as a treatment for non-alcoholic fatty liver disease in children: A systematic review and meta-analysis of randomized controlled trials.
    Chen LH; Wang YF; Xu QH; Chen SS
    Clin Nutr; 2018 Apr; 37(2):516-521. PubMed ID: 28040302
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Therapeutic Effect of Metformin on Chemerin in Non-Obese Patients with Non-Alcoholic Fatty Liver Disease (NAFLD).
    Zhuang X; Sun F; Li L; Jiang D; Li X; Sun A; Pan Z; Lou N; Zhang L; Lou F
    Clin Lab; 2015; 61(10):1409-14. PubMed ID: 26642701
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Fatty acid and non-alcoholic fatty liver disease: Meta-analyses of case-control and randomized controlled trials.
    Guo XF; Yang B; Tang J; Li D
    Clin Nutr; 2018 Feb; 37(1):113-122. PubMed ID: 28161092
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Determinants of hyperglucagonemia in pediatric non-alcoholic fatty liver disease.
    Maruszczak K; Radzikowski K; Schütz S; Mangge H; Bergsten P; Forslund A; Manell H; Pixner T; Ahlström H; Kullberg J; Mörwald K; Weghuber D
    Front Endocrinol (Lausanne); 2022; 13():1004128. PubMed ID: 36133310
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The Relationship between Prebiotic Supplementation and Anthropometric and Biochemical Parameters in Patients with NAFLD-A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
    Stachowska E; Portincasa P; Jamioł-Milc D; Maciejewska-Markiewicz D; Skonieczna-Żydecka K
    Nutrients; 2020 Nov; 12(11):. PubMed ID: 33187278
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effects of lifestyle interventions on clinical characteristics of patients with non-alcoholic fatty liver disease: A meta-analysis.
    Katsagoni CN; Georgoulis M; Papatheodoridis GV; Panagiotakos DB; Kontogianni MD
    Metabolism; 2017 Mar; 68():119-132. PubMed ID: 28183444
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effect of Different Exercise Methods on Non-Alcoholic Fatty Liver Disease: A Meta-Analysis and Meta-Regression.
    Xiong Y; Peng Q; Cao C; Xu Z; Zhang B
    Int J Environ Res Public Health; 2021 Mar; 18(6):. PubMed ID: 33801028
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Liraglutide or insulin glargine treatments improves hepatic fat in obese patients with type 2 diabetes and nonalcoholic fatty liver disease in twenty-six weeks: A randomized placebo-controlled trial.
    Guo W; Tian W; Lin L; Xu X
    Diabetes Res Clin Pract; 2020 Dec; 170():108487. PubMed ID: 33035599
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Vitamin D and nonalcoholic fatty liver disease in children: a randomized controlled clinical trial.
    El Amrousy D; Abdelhai D; Shawky D
    Eur J Pediatr; 2022 Feb; 181(2):579-586. PubMed ID: 34459959
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effects of probiotics on nonalcoholic fatty liver disease: a meta-analysis.
    Ma YY; Li L; Yu CH; Shen Z; Chen LH; Li YM
    World J Gastroenterol; 2013 Oct; 19(40):6911-8. PubMed ID: 24187469
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Efficacy and safety of anti-hyperglycaemic drugs in patients with non-alcoholic fatty liver disease with or without diabetes: An updated systematic review of randomized controlled trials.
    Mantovani A; Byrne CD; Scorletti E; Mantzoros CS; Targher G
    Diabetes Metab; 2020 Nov; 46(6):427-441. PubMed ID: 31923578
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Randomized, vitamin E-controlled trial of bicyclol plus metformin in non-alcoholic fatty liver disease patients with impaired fasting glucose.
    Han Y; Shi JP; Ma AL; Xu Y; Ding XD; Fan JG
    Clin Drug Investig; 2014 Jan; 34(1):1-7. PubMed ID: 24081374
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.